证券之星3 天
君实生物：JS203（CD20/CD3双抗）目前在I期探索研究过程中
证券之星消息，君实生物(688180)01月22日在投资者关系平台上答复投资者关心的问题。 投资者提问：请回答，邹总曾说过JS203，24年四季度或25年一季度 ...
证券之星3 天
君实生物：JS203（CD20/CD3双抗）目前在I期探索研究过程中
证券之星消息，君实生物(688180)01月22日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由智能算法生成（网信算 ...
腾讯网4 天
港股异动 | 康诺亚-B(02162)涨超3% CD20×CD3双抗以NewCo形式出海
消息面上，1月20日，康诺亚和诺诚健华联合宣布，两家公司及其双方的合资公司共同与Prolium Bioscience达成许可合作，授权后者开发和商业化CD20×CD3双 ...
证券之星4 天
港股异动 | 康诺亚-B(02162)涨超3% CD20×CD3双抗以NewCo形式出海
（原标题：港股异动 | 康诺亚-B(02162)涨超3% CD20×CD3双抗以NewCo形式出海） 智通财经APP获悉，康诺亚-B(02162)涨超3%，截至发稿 ...
Pharmabiz28 天
Chugai Pharma receives Japanese regulatory approval for Lunsumio for intravenous infusion ...
Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for “Lunsumio for intravenous infusion 1mg” and “Lunsumio for intravenous infusion 30mg” ...
Fox News5 天
Biden's last-minute pardons of his own family members a 'stain on his legacy,' 'looked ...
CNN reporters and hosts said Monday that President Biden's decision to pardon his family members in the waning minutes of his administration tarnished his reputation and was "a stain on his legacy." ...